MiraBiologics Inc.

MiraBiologics Inc. is a healthcare startup founded in 2017 and headquartered in Japan. The company is focused on breaking through the boundaries of biologics with its innovative LassoGraft Technology, which is based on founding discoveries from the labs of Prof. Takagi and Prof Suga, both of whom are deeply involved in the R&D. MiraBiologics is advancing a robust portfolio of products, including a cMet agonist to tackle NASH/fibrosis, a TrkB agonist to tackle neurodegenerative diseases, an immuno-oncology bi-specific, and undisclosed assets in various stages. The company's pipeline is built on its core RaPID System, which selects highly active cyclic peptides to tightly bind to drug-target proteins and its LassoGraft Technology platform. These technologies enable the creation of Neobiologics, which break multiple current boundaries for biologics. MiraBiologics' approach allows for access across the blood-brain barrier, 3D topological design control, multifunctionality, wide applicability, and faster development speeds that significantly drop development costs. MiraBiologics secured a significant ¥549.00M Venture Round investment on 15 January 2020, with participation from SMBC Venture Capital, SBI Investment, and Shinsei Capital Partners. The company's groundbreaking technologies and promising product portfolio make it an exciting prospect for potential investors in the healthcare and biotech sectors. Their innovative approach to biologics could lead to better, more cost-effective treatments for a range of debilitating diseases.